Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 3Phase 2 2Phase NA 1

Status

Completed 3Unknown 1Terminated 1Active not recruiting 1

Sponsor Class

OTHER 6

Study Type

Interventional 6

Sponsor

Cancer Type

NET 6Endocrine 6CNS 1

Conditions

Neuroendocrine Tumors 6Neuroblastoma 2Meningioma 2Medulloblastoma 2Recurrence 1Lymphoma, Mantle-Cell 1

Interventions

lutetium Lu 177 dotatate 29Everolimus 19Temozolomide 11gallium Ga 68 dotatate 10Nivolumab 10Magnetic Resonance Spectroscopy 10Capecitabine 9pembrolizumab 8lanreotide 8Positron Emission Tomography Computed Tomography 8cabozantinib 73-Iodobenzylguanidine 7177Lu-octreotide, DOTA(0)-Tyr(3)- 7Somatostatin 690Y-octreotide, DOTA-Tyr(3)- 6telotristat ethyl 5lenvatinib 5Octreotide 5Lutetium-177 5Ga(III)-DOTATOC 5Fluorodeoxyglucose F18 5Carboplatin 5avelumab 4Positron-Emission Tomography 4Ipilimumab 4Bevacizumab 4surufatinib 3pasireotide 3fluorodopa F 18 3copper dotatate CU-64 3

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

6 trials
RecentStart dateEnrollment
OTHER × Neuroendocrine Tumors × 90Y-octreotide, DOTA-Tyr(3)- × Clear all
NCT03724409 2023-11-28

Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases

University of Iowa

Phase EARLY_PHASE1 Terminated
3 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03044977 2023-08-16

Study to Evaluate the Safety of Combining Two Radionuclide Therapies to Treat Mid-gut Neuroendocrine Tumors

University of Iowa

Phase EARLY_PHASE1 Active not recruiting
20 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03273712 2023-02-09

Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)

University of Iowa

Phase 2 Completed
39 enrolled 9 charts
CNSEndocrineNET

Medulloblastoma, Meningioma, Neuroblastoma, Neuroendocrine Tumors

NCT04790708 2021-03-10

FENET-2016

University Hospital of Ferrara

Phase NA Unknown
250 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT03197012 2020-07-07

Yttrium-90 DOTA-TOC Intra-arterial (IA) Peptide Receptor Radionuclide Therapy (PRRT) for Neuroendocrine Tumor

University of California, San Francisco

Phase EARLY_PHASE1 Completed
10 enrolled
EndocrineNET

Neuroendocrine Tumors

NCT04296149 2020-03-05

RADIONET

European Institute of Oncology

Phase 2 Completed
5 enrolled
EndocrineNET

Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡